Abbott Laboratories (ABT) Change in Receivables (2009 - 2026)

Abbott Laboratories has disclosed Change in Receivables across 18 years of filings, most recently posting $42.0 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at $42.0 million, down 83.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $432.0 million (down 46.13% YoY), and the FY2025 annual result was $652.0 million, down 5.64% from the prior year.
• Change in Receivables came in at $42.0 million for Q1 2026 at Abbott Laboratories, up from -$222.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $751.0 million in Q1 2022 to a low of -$530.0 million in Q3 2022.
• The 5-year median for Change in Receivables is $158.0 million (2024), against an average of $106.4 million.
• Peak annual rise in Change in Receivables reached 637.14% in 2022, while the deepest fall reached 280.42% in 2022.
• Abbott Laboratories' Change in Receivables stood at -$341.0 million in 2022, then soared by 80.06% to -$68.0 million in 2023, then surged by 332.35% to $158.0 million in 2024, then sank by 240.51% to -$222.0 million in 2025, then jumped by 118.92% to $42.0 million in 2026.
• The last three Change in Receivables figures came in at $42.0 million (Q1 2026), -$222.0 million (Q4 2025), and $202.0 million (Q3 2025), per Business Quant data.